Efficacy and safety of galantamine in patients with dementia with Lewy bodies

A 24-week open-label study

Keith Edwards, Donald Royall, Linda Hershey, David Lichter, Ann Hake, Martin Farlow, Florence Pasquier, Stewart Johnson

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Background: Dementia with Lewy bodies (DLB) is a common dementia of the elderly. A significant cholinergic deficit has been demonstrated that may be responsive to treatment by cholinesterase inhibitors (ChEIs). Methods: A 24-week, open-label study was designed to assess the efficacy and safety of a ChEI, galantamine, in 50 patients with DLB. Results: This study showed beneficial effects with galantamine in 2 of the 3 primary efficacy parameters. The scores on the Neuropsychiatric Inventory (NPI-12) improved by 8.24 points from baseline (p = 0.01) especially in visual hallucinations and nighttime behaviors (p = 0.004). The scores on the Clinician's Global Impression of Change improved by 0.5 points from baseline (p = 0.01). The third primary efficacy parameter, the Cognitive Drug Research Computerized Cognitive Assessment System, was unchanged from baseline. Adverse events were generally mild and transient. Conclusion: Galantamine appears to be an effective and safe therapy for patients with DLB.

Original languageEnglish
Pages (from-to)401-405
Number of pages5
JournalDementia and Geriatric Cognitive Disorders
Volume23
Issue number6
DOIs
StatePublished - May 2007

Fingerprint

Galantamine
Lewy Body Disease
Cholinesterase Inhibitors
Safety
Hallucinations
Cholinergic Agents
Dementia
Equipment and Supplies
Therapeutics
Research
Pharmaceutical Preparations

Keywords

  • Cholinesterase inhibitors
  • Dementia with Lewy bodies
  • Galantamine
  • Visual hallucinations

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology
  • Geriatrics and Gerontology

Cite this

Efficacy and safety of galantamine in patients with dementia with Lewy bodies : A 24-week open-label study. / Edwards, Keith; Royall, Donald; Hershey, Linda; Lichter, David; Hake, Ann; Farlow, Martin; Pasquier, Florence; Johnson, Stewart.

In: Dementia and Geriatric Cognitive Disorders, Vol. 23, No. 6, 05.2007, p. 401-405.

Research output: Contribution to journalArticle

Edwards, Keith ; Royall, Donald ; Hershey, Linda ; Lichter, David ; Hake, Ann ; Farlow, Martin ; Pasquier, Florence ; Johnson, Stewart. / Efficacy and safety of galantamine in patients with dementia with Lewy bodies : A 24-week open-label study. In: Dementia and Geriatric Cognitive Disorders. 2007 ; Vol. 23, No. 6. pp. 401-405.
@article{a9caacc7dee746b39f74d7e1bd8b5788,
title = "Efficacy and safety of galantamine in patients with dementia with Lewy bodies: A 24-week open-label study",
abstract = "Background: Dementia with Lewy bodies (DLB) is a common dementia of the elderly. A significant cholinergic deficit has been demonstrated that may be responsive to treatment by cholinesterase inhibitors (ChEIs). Methods: A 24-week, open-label study was designed to assess the efficacy and safety of a ChEI, galantamine, in 50 patients with DLB. Results: This study showed beneficial effects with galantamine in 2 of the 3 primary efficacy parameters. The scores on the Neuropsychiatric Inventory (NPI-12) improved by 8.24 points from baseline (p = 0.01) especially in visual hallucinations and nighttime behaviors (p = 0.004). The scores on the Clinician's Global Impression of Change improved by 0.5 points from baseline (p = 0.01). The third primary efficacy parameter, the Cognitive Drug Research Computerized Cognitive Assessment System, was unchanged from baseline. Adverse events were generally mild and transient. Conclusion: Galantamine appears to be an effective and safe therapy for patients with DLB.",
keywords = "Cholinesterase inhibitors, Dementia with Lewy bodies, Galantamine, Visual hallucinations",
author = "Keith Edwards and Donald Royall and Linda Hershey and David Lichter and Ann Hake and Martin Farlow and Florence Pasquier and Stewart Johnson",
year = "2007",
month = "5",
doi = "10.1159/000101512",
language = "English",
volume = "23",
pages = "401--405",
journal = "Dementia and Geriatric Cognitive Disorders",
issn = "1420-8008",
publisher = "S. Karger AG",
number = "6",

}

TY - JOUR

T1 - Efficacy and safety of galantamine in patients with dementia with Lewy bodies

T2 - A 24-week open-label study

AU - Edwards, Keith

AU - Royall, Donald

AU - Hershey, Linda

AU - Lichter, David

AU - Hake, Ann

AU - Farlow, Martin

AU - Pasquier, Florence

AU - Johnson, Stewart

PY - 2007/5

Y1 - 2007/5

N2 - Background: Dementia with Lewy bodies (DLB) is a common dementia of the elderly. A significant cholinergic deficit has been demonstrated that may be responsive to treatment by cholinesterase inhibitors (ChEIs). Methods: A 24-week, open-label study was designed to assess the efficacy and safety of a ChEI, galantamine, in 50 patients with DLB. Results: This study showed beneficial effects with galantamine in 2 of the 3 primary efficacy parameters. The scores on the Neuropsychiatric Inventory (NPI-12) improved by 8.24 points from baseline (p = 0.01) especially in visual hallucinations and nighttime behaviors (p = 0.004). The scores on the Clinician's Global Impression of Change improved by 0.5 points from baseline (p = 0.01). The third primary efficacy parameter, the Cognitive Drug Research Computerized Cognitive Assessment System, was unchanged from baseline. Adverse events were generally mild and transient. Conclusion: Galantamine appears to be an effective and safe therapy for patients with DLB.

AB - Background: Dementia with Lewy bodies (DLB) is a common dementia of the elderly. A significant cholinergic deficit has been demonstrated that may be responsive to treatment by cholinesterase inhibitors (ChEIs). Methods: A 24-week, open-label study was designed to assess the efficacy and safety of a ChEI, galantamine, in 50 patients with DLB. Results: This study showed beneficial effects with galantamine in 2 of the 3 primary efficacy parameters. The scores on the Neuropsychiatric Inventory (NPI-12) improved by 8.24 points from baseline (p = 0.01) especially in visual hallucinations and nighttime behaviors (p = 0.004). The scores on the Clinician's Global Impression of Change improved by 0.5 points from baseline (p = 0.01). The third primary efficacy parameter, the Cognitive Drug Research Computerized Cognitive Assessment System, was unchanged from baseline. Adverse events were generally mild and transient. Conclusion: Galantamine appears to be an effective and safe therapy for patients with DLB.

KW - Cholinesterase inhibitors

KW - Dementia with Lewy bodies

KW - Galantamine

KW - Visual hallucinations

UR - http://www.scopus.com/inward/record.url?scp=34250213269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250213269&partnerID=8YFLogxK

U2 - 10.1159/000101512

DO - 10.1159/000101512

M3 - Article

VL - 23

SP - 401

EP - 405

JO - Dementia and Geriatric Cognitive Disorders

JF - Dementia and Geriatric Cognitive Disorders

SN - 1420-8008

IS - 6

ER -